Entacapone‐Induced Hepatotoxicity and Hepatic Dysfunction
- 26 November 2002
- journal article
- case report
- Published by Wiley in Movement Disorders
- Vol. 17 (6) , 1362-1365
- https://doi.org/10.1002/mds.10342
Abstract
We describe 2 patients with Parkinson's disease who developed hepatotoxicity associated with the use of entacapone, a novel, mainly peripheral acting inhibitor of catechol‐D‐methyltransferase. Hepatotoxicity resolved rapidly with discontinuation of the drug. Analysis of causality in a further case initially linked to entacapone exposure was confounded by conflicting serial adverse reaction reports. © 2002 Movement Disorder SocietyKeywords
This publication has 15 references indexed in Scilit:
- Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the ratJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 2001
- Causality Assessment Versus Guilt–By–Association in Drug HepatotoxicityHepatology, 2001
- Twelve‐month safety of entacapone in patients with Parkinson’s diseaseEuropean Journal of Neurology, 2001
- Gamma Glutamyl TransferaseCritical Reviews in Clinical Laboratory Sciences, 2001
- DRUG-INDUCED LIVER DISEASEMedical Clinics of North America, 2000
- DRUG-INDUCED LIVER DISEASEClinics in Liver Disease, 2000
- COMT inhibition in the treatment of Parkinson’s diseaseZeitschrift für Neurologie, 1998
- Serum Lactic Dehydrogenase in the Differential Diagnosis of Acute Hepatocellular InjuryJournal of Clinical Gastroenterology, 1994
- Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuriesJournal of Clinical Epidemiology, 1993
- A method for estimating the probability of adverse drug reactionsClinical Pharmacology & Therapeutics, 1981